Aqua Metals Joins $4.99 Million DOE Grant Project to Pioneer Domestic Critical Mineral Supply Chain RENO, Nev., May 10, 2024 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling technology, is proud to announce its collaboration in a significant U.S. Department of Energy (DOE) grant project. As part of a consortium led by Pennsylvania State University, Aqua Metals will play a crucial role in the $4.99 million initiative aimed at establishing a fully domestic supply chain for critical minerals essential for modern technologies, from e...
A director at Landmark Bancorp Inc bought 1,050 shares at 18.961USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Aqua Metals to Announce First Quarter 2024 Financial Results and Host Investor Conference Call on May 15, 2024 RENO, Nev., May 09, 2024 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, today announced it will report financial results for the first quarter ended March 31, 2024, and provide a business update after the market closes on Wednesday, May 15, 2024. Following the release, management will host a conference call that same day at 4:30 p.m. ET. The live conference call can be accessed at or from the investor relations sect...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. “The IMPALA-2 trial remains on-track and we look forward to reporting top line results by the end of the second quarter,” said Matt Pauls, Chair and CEO, Savara. “Following that, and assuming positive data, we expect to file a BLA in the first half of 2025. Importantly, with $143 million in cash and investments, we believe we are capitalized into ...
Epsilon Reports First Quarter 2024 Results HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported first quarter 2024 financial and operating results. Epsilon’s highlights for first quarter 2024 include: Net revenue interest (NRI) total production of 2.0 Bcfe (21.8 MMcfe per day, 16% liquids) for the quarter ended March 31, 2024, a decrease of 11% compared to the prior quarter. 1.7 Bcf net revenue interest (NRI) natural gas production, a decrease of 16% compared to the prior quarter 44% of the decrease (0.2 Bcf) is att...
HighPeak Energy, Inc. Announces First Quarter 2024 Financial and Operating Results FORT WORTH, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2024. HighlightsFirst Quarter 2024 Sales volumes averaged 49,729 barrels of crude oil equivalent per day (“Boe/d”), consisting of 80% crude oil and 91% liquids, representing a 34% increase over first quarter 2023.Lease operating expenses, excluding expense workovers, were reduced for the fourth consecutive qua...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. “We continue to focus on enrollment in the two clinical studies for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008, and we are pleased with the progress,” said David Campbell, Ph.D., President and CEO ...
Enphase Energy Expands IQ8 Commercial Microinverter Deployments in North America FREMONT, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that installers of Enphase® products across North America have seen growing deployments of IQ8™ Commercial Microinverters. A recent Wood Mackenzie report estimated that only 5.1% of viable U.S. commercial properties had solar installations by the end of 2023. IQ8 Commercial Microinverters , enabling solar insta...
A director at Enphase Energy Inc bought 4,000 shares at 104.243USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended March 31, 2024 and Declaration of Distributions on Common Stock for the Months Ending July 31, August 31, and September 30, 2024 GREENWICH, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended March 31, 2024. On April 25, 2024, our Board of Directors declared the following distributions on our com...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.